Program
apatinib
Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 344 open or running | phase 3since Jan 13, 2012 | Aug 30, 2010 | none ahead |
| Elevar Therapeuticsits history only | 70 open or running | phase 3since Jan 24, 2017 | Dec 18, 2011 | none ahead |
| Bukwang Pharmaceuticalits history only | 10 open or running | phase 1since Feb 26, 2016 | Feb 26, 2016 | none ahead |
| GrandPharma (China)its history only | 11 open or running | phase 2since Aug 13, 2025 | Aug 13, 2025 | Dec 30, 2027phase 2 · NCT07334483 |
| Guangzhou Virotech Pharmaceuticalits history only | 11 open or running | phase 3since May 8, 2026 | May 8, 2026 | Dec 31, 2028phase 3 · NCT07589244 |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| HRYZ Biotechits history only | 11 open or running | early phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 2since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Bukwang Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Aug 30, 2010.
- Apr 8, 2020Phase 1 study in Healthy SubjectsJiangsu HengRui Medicine · NCT04341090 · 42 enrolled · China
- Apr 9, 2020Phase 3 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT04342910 · 550 planned · China
- May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
- May 13, 2020Phase 1 study in NSCLCJiangsu HengRui Medicine · NCT04390984 · 22 enrolled · China
- Jun 1, 20202 phase 1 studiesJiangsu HengRui Medicine · NCT04414852, NCT04457180
- Aug 16, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04517357 · 100 enrolled · China
- Nov 19, 2020Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT04639180 · 687 enrolled · China
- Apr 26, 2021Phase 2 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT04869488 · 93 enrolled · China
- Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Jiangsu HengRui Medicine · NCT04985136 · 1 enrolled · China
- Mar 10, 2022Phase 1 study in HealthyElevar Therapeutics · NCT05287360 · 60 enrolled · United States
- Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT05320692 · 423 enrolled · China
- Jan 7, 2025Hansoh Pharmaceutical Group’s first study: phase 1 study in Ovarian NeoplasmsNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
- Aug 13, 2025GrandPharma (China)’s first study: phase 2 study in HCCNew to GrandPharma (China)GrandPharma (China) · NCT07334483 · 120 planned · China
- May 8, 2026Guangzhou Virotech Pharmaceutical’s first study: phase 3 study in HCCNew to Guangzhou Virotech PharmaceuticalGuangzhou Virotech Pharmaceutical · NCT07589244 · 66 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in HCCGrandPharma (China) · NCT07334483
- Dec 31, 2028Primary completion: phase 3 study in HCCGuangzhou Virotech Pharmaceutical · NCT07589244
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07589244HCC · China | 3 | Recruiting | Guangzhou Virotech Pharmaceutical | Dec 31, 2028 | 66 |
| NCT07334483HCC · China | 2 | Recruiting | GrandPharma (China) | Dec 30, 2027 | 120 |
| NCT06769425Ovarian Neoplasms · China | 1 | Recruiting | Hansoh Pharmaceutical Group | May 7, 2026 | 157 |
| NCT05320692Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 30, 2026 | 423 |
| NCT05287360Healthy · United States | 1 | Completed | Elevar Therapeutics | Mar 16, 2022 | 60 |
| NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Terminated | Jiangsu HengRui Medicine | Dec 29, 2021 | 1 |
| NCT04869488Metastatic Castration Resistant Prostate Cancer · China | 2 | Completed | Jiangsu HengRui Medicine | Feb 14, 2023 | 93 |
| NCT04639180Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 31, 2026 | 687 |
| NCT04517357Ovarian Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 30, 2023 | 100 |
| NCT04457180Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | May 20, 2021 | 18 |
| NCT04414852Subjects With Impaired Renal Function and Healthy Subjects | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 15, 2021 | 24 |
| NCT04390984NSCLC · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 2021 | 22 |
| NCT04383977Ovarian Neoplasms | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2020 | 54 |
| NCT04342910Stomach Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 1, 2026 | 550 |
| NCT04341090Healthy Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Jul 6, 2020 | 42 |
| NCT04335006Breast Neoplasms · China | 3 | Terminated | Jiangsu HengRui Medicine | Apr 14, 2023 | 80 |
| NCT04322552Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 3, 2021 | 18 |
| NCT04296370Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation · China | 3 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2022 | 474 |
| NCT04229615Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jun 30, 2023 | 690 |
| NCT04203485PD-L1 Positive Non-small Cell Lung Cancer | 3 | UNKNOWN | Jiangsu HengRui Medicine | Mar 31, 2022 | 762 |
| NCT04119453Carcinoma, Adenoid Cystic · United States, South Korea | 2 | Terminated | Elevar Therapeutics | Jun 28, 2023 | 80 |
| NCT04074564Sarcoma · China | Early 1 | Recruiting | HRYZ Biotech | Aug 7, 2024 | 60 |
| NCT04073615Colorectal Neoplasms · United States | 1 | Terminated | Elevar Therapeutics | May 31, 2023 | 29 |
| NCT04000295Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jan 2021 | 280 |
| NCT03945604Triple Negative Breast Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 9, 2021 | 32 |
| NCT03711279Sarcoma · China | 2 | Terminated | Jiangsu HengRui Medicine | Jun 21, 2021 | 99 |
| NCT03707028Stomach Neoplasms · Korea, Republic of | 2 | Terminated | Elevar Therapeutics | Aug 24, 2021 | 12 |
| NCT03491631Neoplasms · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jun 2023 | 23 |
| NCT03472365Stomach Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 25, 2020 | 67 |
| NCT03463876Carcinoma, Hepatocellular · China | 2 | Completed | Jiangsu HengRui Medicine | Mar 10, 2021 | 190 |
| NCT03396211Neoplasms · United States | 1 | Completed | Elevar Therapeutics | Oct 28, 2020 | 30 |
| NCT03267654Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Qilu Pharmaceutical | Oct 20, 2020 | 100 |
| NCT03245307Cytochrome P450 Interaction · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Apr 30, 2018 | 20 |
| NCT03075462Ovarian Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 98 |
| NCT03042611Stomach Neoplasms · United States, France, Germany and more | 3 | Completed | Elevar Therapeutics | Feb 15, 2019 | 460 |
| NCT03026881Recurrence · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Apr 2018 | 24 |
| NCT02836171Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 2017 | 20 |
| NCT02836821Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 2017 | 20 |
| NCT02764268Stomach Neoplasms · China | – | Completed | Jiangsu HengRui Medicine | Dec 10, 2018 | 60 |
| NCT02711969Stomach Neoplasms · Korea, Republic of | 1 | Completed | Bukwang Pharmaceutical | Nov 2016 | 6 |
| NCT02332512Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Aug 2017 | 417 |
| NCT02329860Carcinoma, Hepatocellular · China | 3 | Completed | Jiangsu HengRui Medicine | Dec 15, 2017 | 400 |
| NCT01531777Colorectal Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 2014 | 40 |
| NCT01512745Stomach Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | May 2013 | 267 |
| NCT01497704Neoplasms · United States, Korea, Republic of | 2 | Completed | Elevar Therapeutics | Feb 2015 | 55 |
| NCT01270386Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jiangsu HengRui Medicine | Jul 2011 | 136 |
| NCT01192971Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Jul 2013 | 121 |
How it is read
Names in the registry
- “Apatinib”, 13 entries
- “Rivoceranib”, 5 entries
- “Apatinib Mesylate”, 5 entries
- “apatinib”, 3 entries
- “Fluzoparib+Apatinib”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 8 studies
- Ovarian Neoplasms, 6 studies
- Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.